Pipeline

TRN

Candidate & Indication

Discovery

IND-enabling

Phase 1

Phase 2

Phase 3

IRF4

KB-9558
(p300 KAT inhibitor)

R/R Multiple Myeloma

MYC

Undisclosed

β-Catenin

Undisclosed

Undis-closed

Discovery Collaboration

Genentech

Multiple

Undisclosed

Additional proprietary programs from mapping and screening the MYC, AR, MYB, IRF4 and other TRNs

KAT: lysine acetyltransferase. IRF4: interferon regulatory factor 4. TF: transcription factor. TRN: transcription regulatory network.

We may not be successful in identifying product candidates that can selectively modulate the specific oncogenic TRNs associated with such programs.